[go: up one dir, main page]

WO2004111019A3 - Groupement protecteur clivable par les albumines seriques - Google Patents

Groupement protecteur clivable par les albumines seriques Download PDF

Info

Publication number
WO2004111019A3
WO2004111019A3 PCT/FR2004/001466 FR2004001466W WO2004111019A3 WO 2004111019 A3 WO2004111019 A3 WO 2004111019A3 FR 2004001466 W FR2004001466 W FR 2004001466W WO 2004111019 A3 WO2004111019 A3 WO 2004111019A3
Authority
WO
WIPO (PCT)
Prior art keywords
serumal
protective groups
albumins
groups cleavable
cleavable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2004/001466
Other languages
English (en)
Other versions
WO2004111019A2 (fr
Inventor
Charles Tellier
Jacques Lebreton
Thierry Dintinger
Valerie Fargeas
Sylvain Robin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite de Nantes
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite de Nantes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite de Nantes filed Critical Centre National de la Recherche Scientifique CNRS
Publication of WO2004111019A2 publication Critical patent/WO2004111019A2/fr
Publication of WO2004111019A3 publication Critical patent/WO2004111019A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

L'invention concerne l'utilisation des composés de la formule générale (I) en tant que groupement protecteur, notamment de composés bioactifs ou chromogènes, clivable par les albumines sériques.
PCT/FR2004/001466 2003-06-12 2004-06-11 Groupement protecteur clivable par les albumines seriques Ceased WO2004111019A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR03/07094 2003-06-12
FR0307094A FR2856060A1 (fr) 2003-06-12 2003-06-12 Groupement protecteur clivable par les albumines seriques

Publications (2)

Publication Number Publication Date
WO2004111019A2 WO2004111019A2 (fr) 2004-12-23
WO2004111019A3 true WO2004111019A3 (fr) 2005-04-21

Family

ID=33484390

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2004/001466 Ceased WO2004111019A2 (fr) 2003-06-12 2004-06-11 Groupement protecteur clivable par les albumines seriques

Country Status (2)

Country Link
FR (1) FR2856060A1 (fr)
WO (1) WO2004111019A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115246934B (zh) * 2022-01-26 2023-07-18 郑州大学第一附属医院 2-(1-甲基四氮唑)-4,5-咪唑二甲羧铁(ii)配合物及制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001081328A2 (fr) * 2000-04-24 2001-11-01 Aryx Therapeutics Compositions et methodes destinees au traitement du diabete, de l'hyperlipidemie, de l'hypercholesterolemie et de l'atherosclerose
WO2003024943A2 (fr) * 2000-04-24 2003-03-27 Aryx Therapeutics Matieres et procedes pour le traitement de diabetes, de l'hyperlipidemie, de l'hypercholesterolemie, et de l'atherosclerose

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001081328A2 (fr) * 2000-04-24 2001-11-01 Aryx Therapeutics Compositions et methodes destinees au traitement du diabete, de l'hyperlipidemie, de l'hypercholesterolemie et de l'atherosclerose
WO2003024943A2 (fr) * 2000-04-24 2003-03-27 Aryx Therapeutics Matieres et procedes pour le traitement de diabetes, de l'hyperlipidemie, de l'hypercholesterolemie, et de l'atherosclerose

Also Published As

Publication number Publication date
FR2856060A1 (fr) 2004-12-17
WO2004111019A2 (fr) 2004-12-23

Similar Documents

Publication Publication Date Title
WO2003093269A3 (fr) Pyrazolopyrimidine-4-one substituee
WO2003074500A3 (fr) Nouveaux composes
WO2003016282A3 (fr) Nouveaux 1h-dihydropyrazoles substitues et leurs procedes de preparation et d'utilisation
WO2006005609A3 (fr) Derives d'oxindole substitues, et medicaments les renfermant
WO2006032342A3 (fr) Medicament contenant des composes carbonyles et leur utilisation
WO2004069152A3 (fr) ?4,5 glycuronidase et ses utilisations
CA2523831A1 (fr) 5,7-diaminopyrazolo[4,3]d!pyrimidines utiles pour le traitement de l'hypertension
MXPA05011522A (es) Derivados de 2-acilamino-4-feniltiazol, metodo para su preparacion y su aplicacion en terapeutica.
WO2004018451A8 (fr) Derives de pyridazinone utilises comme inhibiteurs de pde4
WO2003008404A3 (fr) Sels de sulfonium, procedes de preparation associes et utilisation de ces sels en tant que photoinitiateurs dans des systemes durcissables par rayonnement
MX2007006397A (es) Derivados de tetrahidropirano.
WO2007112028A3 (fr) Phosphonates de 2'-fluoronucléoside en tant qu'agents antiviraux
WO2004014893A3 (fr) Quinolones anti-microbiens, leurs compositions et utilisation
WO2004062613A3 (fr) Inhibiteurs d'integrase hiv
PL1613304T3 (pl) Inhibitory DPP-IV
WO2003059903A3 (fr) Derives substitues de 4-aminopyridine
WO2001082909A3 (fr) Derives de 2-acyl-indole et leur utilisation comme agents antitumoraux
WO2006072458A3 (fr) Derives d'oxindol substitues, agents pharmaceutiques les contenant, et leur utilisation
WO2001098275A3 (fr) 1-aryl-4-oxo-1,4-dihydro-3-quinolinecarboxamides utilises comme agents antiviraux
WO2002064574A3 (fr) Antibactériens à base de pyridoarylphényle oxazolidinone, compositions et procédés associés
WO2005051083A3 (fr) Composes molluscicides et anti-anatifes
WO2004056832A3 (fr) Derives d'epothilone
WO2006019955A3 (fr) Methodes et compositions antivirales
WO2006088903A3 (fr) Composes pyrazole
WO2005110421A3 (fr) Formulation d'aerosol pour l'inhalation de beta-agonistes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase